关键词: 非小细胞肺癌, 肿瘤突变负荷, 表皮生长因子受体, 二代测序, 全面基因组测序, 预后

Abstract: The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) has significantly improved the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, there are still a portion of patients with poor efficacy and prognosis. Therefore, it is urgently needed to find effective emerging prognostic markers. In the past few years, tumor mutational burden (TMB) was mainly used to screen patients who benefitted from immunotherapy and predict the efficacy. Recently, there are also corresponding exploratory studies on EGFR-mutant NSCLC. In this review, we summarized the challenges of TMB test and latest clinical research in EGFR-mutant advanced NSCLC.

Key words: Non-small cell lung cancer, Tumor mutational burden, Epidermal growth factor receptor, Next-generation sequencing, Comprehensive genomic profiling, Prognosis